EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Discovery of novel 2-aminopyridine derivatives as ROS1 and ALK dual inhibitors to combat drug-resistant mutants including ROS1 G2032R and ALK G1202R

Siming Liu, Chuan Huang, Chunhui Huang, Yaqi Huang, Yonghuan Yu, Guowu Wu, Fengqiu Guo, Ying Jiang, Shanhe Wan, Zhengguang Zhu, Yuanxin Tian, Jianghua Zhu und 1 weitere

Journal of Enzyme Inhibition and Medicinal Chemistry · 2023

DOI: 10.1080/14756366.2023.2227779 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Enzyme Inhibition and Medicinal Chemistry, 2023. Verfasst von Siming Liu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Affiliated Foshan Maternity & Child Healthcare Hospital, Southern Medicinal University (Foshan Maternity & Child Healthcare Hospital), Foshan, China. Hauptthemen laut MEDLINE: Protein-Tyrosine Kinases, Lung Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: China postdoctoral Science Foundation, Natural Science Foundation of Guangdong Province, Key Research and Development Plan of Guangzhou.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Clinical treatment by FDA-approved ROS1/ALK inhibitor Crizotinib significantly improved the therapeutic outcomes. However, the emergence of drug resistance, especially driven by acquired mutations, have become an inevitable problem and worsened the clinical effects of Crizotinib. To combat drug resistance, some novel 2-aminopyridine derivatives were designed rationally based on molecular simulation, then synthesised and subjected to biological test. The preferred spiro derivative C01 exhibited remarkable activity against CD74-ROS1G2032R cell with an IC50 value of 42.3 nM, which was about 30-fold more potent than Crizotinib. Moreover, C01 also potently inhibited enzymatic activity against clinically Crizotinib-resistant ALKG1202R, harbouring a 10-fold potency superior to Crizotinib. Furthermore, molecular dynamic disclosed that introducing the spiro group could reduce the steric hindrance with bulky side chain (Arginine) in solvent region of ROS1G2032R, which explained the sensitivity of C01 to drug-resistant mutant. These results indicated a path forward for the generation of anti Crizotinib-resistant ROS1/ALK dual inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein-Tyrosine KinasesLung NeoplasmsHumansAnaplastic Lymphoma KinaseDrug Resistance, NeoplasmProto-Oncogene ProteinsCrizotinibProtein Kinase InhibitorsMutationCell Line, TumorAminopyridines

Stichwörter der Autor:innen

anti-drug-resistant2-Aminopyridine derivatives ROS1/ALK dual inhibitors ROS1G2032RALKG1202R

Substanzen

Protein-Tyrosine KinasesAnaplastic Lymphoma KinaseProto-Oncogene ProteinsCrizotinibProtein Kinase Inhibitorsalpha-aminopyridineAminopyridinesROS1 protein, human

Autor:innen und Institutionen

  • Affiliated Foshan Maternity & Child Healthcare Hospital, Southern Medicinal University (Foshan Maternity & Child Healthcare Hospital), Foshan, China.
  • Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China.

Förderung

  • China postdoctoral Science Foundation
  • Natural Science Foundation of Guangdong Province
  • Key Research and Development Plan of Guangzhou

Zitieren

APA

Liu, S., Huang, C., Huang, C., Huang, Y., Yu, Y., Wu, G., Guo, F., Jiang, Y., Wan, S., Zhu, Z., Tian, Y., Zhu, J., & Zhang, J. (2023). Discovery of novel 2-aminopyridine derivatives as ROS1 and ALK dual inhibitors to combat drug-resistant mutants including ROS1 G2032R and ALK G1202R. Journal of Enzyme Inhibition and Medicinal Chemistry. https://doi.org/10.1080/14756366.2023.2227779

Vancouver

Liu S, Huang C, Huang C, Huang Y, Yu Y, Wu G, et al. Discovery of novel 2-aminopyridine derivatives as ROS1 and ALK dual inhibitors to combat drug-resistant mutants including ROS1 G2032R and ALK G1202R. Journal of Enzyme Inhibition and Medicinal Chemistry. 2023. doi:10.1080/14756366.2023.2227779

BibTeX
@article{Liu2023,
  author = {Liu, Siming and Huang, Chuan and Huang, Chunhui and Huang, Yaqi and Yu, Yonghuan and Wu, Guowu and Guo, Fengqiu and Jiang, Ying and Wan, Shanhe and Zhu, Zhengguang and Tian, Yuanxin and Zhu, Jianghua and Zhang, Jiajie},
  title = {Discovery of novel 2-aminopyridine derivatives as ROS1 and ALK dual inhibitors to combat drug-resistant mutants including ROS1 G2032R and ALK G1202R},
  journal = {Journal of Enzyme Inhibition and Medicinal Chemistry},
  year = {2023},
  doi = {10.1080/14756366.2023.2227779}
}
Kostenlos starten →